TP53 and neoplasm: In this work, the antitumor activity was observed with EGCG and the adjuvant treatment of VCR/EGCG, by inhibiting tumor growth and increasing survival, possibly through increasing p53 and decreasing Bcl2, observing a greater effect in the concomitant treatment VCR/EGCG for Bcl2.